OTCM
SGIHY
Market cap2.95bUSD
, Last price
USD
Name
Sugi Holdings Co Ltd
Chart & performance
P/E
—
P/S
—
EPS
120.88
Div yield, %
—
Shrs. gr., 5y
14.31%
Rev. gr., 5y
10.07%
Revenues
1.01t
+15.07%
Net income
44.98b
+75.10%
CFO
86.78b
+134.91%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sugi Holdings Co.,Ltd. manages a network of approximately 1,483 drugstores throughout Japan. Beyond its retail pharmacy operations, the company offers a diverse portfolio of health and social support services. These include providing health counseling, facilitating home-visit prescription dispensing and nursing care, and offering medical consulting. Additionally, Sugi Holdings champions disabled employment initiatives and provides comprehensive elderly home care assistance. The company was established in 1976 and maintains its corporate headquarters in Obu, Japan.
Key people
Katsunori Sugiura
President, President of Subsidiary, Representative Director · since 2021
Shinya Sugiura
Vice President, President of Subsidiary, Representative Director · since 2025
Toshihiko Asaka
Executive Officer · since 2026
Toshiyuki Hantani
Executive Officer · since 2026
Makoto Kasai
Executive Officer · since 2024
Mari Konagaya
Executive Officer, Director of Legal Affairs · since 2026
Satoshi Kubo
Executive Officer · since 2024
Shigeki Mori
Executive Officer · since 2024
Kenta Morii
Executive Officer · since 2026
Kazuya Morinaga
Executive Officer · since 2024
Tomohiro Shiraishi
Executive Officer · since 2025
Tsuyoshi Yamamoto
Executive Officer · since 2024
Eiichi Sakakibara
Chairman of the Board, Chairman of Subsidiary · since 2025
Shigeyuki Kamino
Independent Director · since 2015
Kaseri Oura
Independent Director · since 2024
Independent Director · since 2024
Shiro Uchida
Independent Director · since 2024
Headquarters & legal address
三河安城町１丁目８番地４
安城市, 23 446-0056
JP
安城市, 23 446-0056
JP
Other language
Sugi Holdings Co., Ltd.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑02 | 2025‑02 | 2024‑02 | 2024‑02 | 2023‑02 | 2022‑02 | 2021‑02 | 2020‑02 | 2020‑02 | 2019‑02 | 2018‑02 | 2017‑02 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||